ArticleThe Journal of clinical endocrinology and metabolism2011
Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays.
Article in The Journal of clinical endocrinology and metabolism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 65 citations in OpenAlex.
- Trial
- Serum sclerostin as a marker of microvascular and macrovascular complications among children and adolescents with type 1 diabetes mellitus.Pediatric nephrology (Berlin, Germany) · 2025Article
- Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus.Journal of clinical & translational endocrinology · 2025Article
- Serum sclerostin is associated with recurrent kidney stone formation independent of hypercalciuria.Clinical kidney journal · 2024Article
- Sclerostin: From Molecule to Clinical Biomarker.International journal of molecular sciences · 2022Review
- Sclerostin and Osteocalcin: Candidate Bone-Produced Hormones.Frontiers in endocrinology · 2021Review
- Article
- The Osteocyte as the New Discovery of Therapeutic Options in Rare Bone Diseases.Frontiers in endocrinology · 2020Review
- Chronic Kidney Disease Is Associated With Greater Bone Marrow Adiposity.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2018Article
- Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway.Nature reviews. Endocrinology · 2018Review
- Article
- Novel bone metabolism-associated hormones: the importance of the pre-analytical phase for understanding their physiological roles.Endocrine · 2017Review
- Review
- How Accurate is Your Sclerostin Measurement? Comparison Between Three Commercially Available Sclerostin ELISA Kits.Calcified tissue international · 2016Article
- Sclerostin and CKD-MBD.Current osteoporosis reports · 2015Review
- Circulating sclerostin associated with vertebral bone marrow fat in older men but not women.The Journal of clinical endocrinology and metabolism · 2014Article
- Reduced renal calcium excretion in the absence of sclerostin expression: evidence for a novel calcium-regulating bone kidney axis.Journal of the American Society of Nephrology : JASN · 2014Review
- Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.Journal of pharmacokinetics and pharmacodynamics · 2014Article
- Comparison of two commercially available ELISAs for circulating sclerostin.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2014Article
- The alliance of mesenchymal stem cells, bone, and diabetes.International journal of endocrinology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundSclerostin alters bone formation. The precise and reproducible measurement of sclerostin concentrations in biological samples is important for assessment of metabolic bone disease. We determined sclerostin concentrations in serum and plasma using two commercially available ELISA.
methodsWe measured sclerostin concentrations in serum or heparin-plasma obtained from 25 normal human subjects using two commercial ELISA available from Biomedica Medizinprodukte GmbH and TECOmedical AG.
resultsWith the Biomedica assay, serum sclerostin concentrations were 0.99 ± 0.12 ng/ml (mean ± sem), and plasma concentrations were 1.47 ± 0.13 ng/ml (paired t test, P < 0.001). With the TECO assay, serum sclerostin levels were 0.71 ± 0.05 ng/ml, and plasma sclerostin concentrations were 0.80 ± 0.06 ng/ml (paired t test, P < 0.001). Serum and plasma sclerostin concentrations were significantly different when determined by the two assays (serum, P = 0.015; plasma, P < 0.001). Recovery of added recombinant sclerostin to serum was less than expected with both Biomedica and TECO assays (P < 0.001, paired t test).
conclusionsThe concentrations of sclerostin in serum and plasma are different when determined by the two assays. Serum or plasma sclerostin concentrations with current assays should be interpreted with caution. The data suggest that the same assay should be used for comparing groups of patients or patients being followed longitudinally. Standardization of sclerostin assays is required before being introduced into general clinical laboratory use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.